Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electroc...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Sanofi
Collaborators
NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer
NCT04541381 · Gastrointestinal Cancer, Head and Neck Cancer, and more
NCT06340568 · Endometrial Cancer
NCT07489378 · Very Rare Tumors, Very Rare Cancers, and more
NCT07549477 · Adult Cancer Patients, Right Atrial Clot
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey
Sanofi-Aventis Administrative Office
Diegem
Sanofi-Aventis Administrative Office
Hørsholm
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions